Most immunology researchers and cell therapy program managers evaluating leukopak suppliers eventually arrive at the same shortlist. OrganaBio and HemaCare, now part of Charles River Laboratories, are two of the names that appear most often. Both supply GMP and research-grade leukapheresis products. Both can support apheresis collections for clinical programs. But the way they’re built is fundamentally different, and those structural differences produce different outcomes depending on what your program actually needs.
This comparison is not a feature grid. It is a working guide for researchers and procurement teams who need to understand what they’re actually choosing between, and where the specs on paper diverge from the quality picture in practice.
Company Backgrounds
OrganaBio is an independent cell therapy CTDMO with owned Cell Processing Centers in San Diego and Chicago. The company operates its own GMP manufacturing facility, runs its own donor apheresis network, and processes all leukapheresis product in-house under a harmonized quality management system. The 2026 integration of Excellos Labs extended OrganaBio’s CTDMO capabilities to include downstream manufacturing steps. OrganaBio’s differentiation is built around two structural facts: owned processing facilities and a 30-minute receipt-to-first-centrifuge-spin standard that eliminates overnight shipping from the fresh leukapheresis supply chain.
HemaCare was founded in 1979 and was acquired by Charles River Laboratories in 2020. As part of Charles River, HemaCare operates as one component of a larger contract research and manufacturing organization with capabilities across drug discovery, safety assessment, and biologics manufacturing. HemaCare’s cell therapy focus sits within a diversified CRO. Their apheresis network is among the largest in the industry, and their scale advantage — frequently cited as 400,000+ apheresis collections since founding — is a real operational capability for programs that need volume.
How the Products Compare
PBMC Viability: Spec Minimums vs. Documented Averages
The most consequential difference between how these two suppliers position their products is the gap between floor specifications and documented averages.
HemaCare’s published PBMC viability specification is 90% or greater post-thaw for cryopreserved product, which is the industry standard minimum. Meeting the floor spec is not the same as performing at the floor spec, but when a supplier publishes a 90% minimum, it is telling you where their quality control threshold sits, not where typical performance lands.
OrganaBio’s Cell Processing Centers achieve greater than 99% average PBMC viability for healthy donor material processed under the 30-minute receipt-to-first-spin standard. This is not a floor spec. It is documented average performance across fresh collections processed at owned facilities, where the time window between apheresis completion and density gradient separation is under 30 minutes. The difference matters because PBMC viability measured immediately post-processing tells you something real about the cell population, but it does not fully predict functional performance, especially when there are hours between collection and processing in which cell populations have already experienced quality degradation.
Published cell biology research has documented that PBMC samples with viability scores above 90% can exhibit complete loss of response to mitogenic stimulation following handling delays. A high viability number from a sample processed 20 hours post-collection is not the same thing as a high viability number from a sample processed 25 minutes post-collection, even when the numbers look the same on a COA.
Processing Infrastructure: Owned Facilities vs. Third-Party Network
HemaCare’s apheresis and processing network operates through a combination of owned and affiliated collection sites. At Charles River’s scale, the network is large. For programs that need volume and geographic reach, this is a real capability. The tradeoff is that third-party network processing introduces variability that is difficult to control through SOPs alone, and that the chain-of-custody from collection to processing to finished material passes through more organizational handoffs than an owned-facility model.
OrganaBio’s Cell Processing Centers are owned and operated by OrganaBio under a single harmonized quality management system. Every collection that flows through the CPC network is processed by OrganaBio personnel under OrganaBio SOPs in OrganaBio-controlled facilities. There is no handoff to an affiliated partner. The consistency between a collection processed in San Diego and a collection processed in Chicago is maintained through the same quality system, not through contractual requirements on third parties.
For programs at Phase I/II where the starting material supply chain is one of the variables being characterized for comparability purposes, the difference between owned-facility processing and network processing is a real supply chain risk question, not an abstract preference.
Receipt-to-Processing Time
| Supplier | Processing Model | Typical Receipt-to-First-Spin |
|---|---|---|
| OrganaBio | Owned CPC network (San Diego, Chicago) | Under 30 minutes |
| HemaCare (Charles River) | Central processing + network | 18-24+ hours (overnight shipment for out-of-market collections) |
The 30-minute window is OrganaBio’s standard for the time from when the leukapheresis product is received at the CPC to when the first centrifuge spin begins. For collections performed at or near the CPC, this window starts immediately at collection completion. This is the processing parameter most directly correlated with PBMC phenotype preservation, monocyte contamination profile, and functional capacity of the isolated cells.
HemaCare’s overnight shipment model means that out-of-market collections travel up to 24 hours before processing begins. For healthy donor material in standard immunology research applications, this is often acceptable. For programs where starting material quality has documented downstream manufacturing consequences, the overnight window introduces a variable that cannot be fully controlled after the fact.
GMP Capabilities
Both suppliers offer GMP-compliant leukapheresis and PBMC products. HemaCare has an established GMP track record as part of the Charles River biologics manufacturing platform. OrganaBio’s GMP capability is built around its owned CPC and manufacturing infrastructure, with the Excellos integration adding downstream cGMP manufacturing under the same quality system.
The structural difference at the GMP level mirrors the research-grade difference: HemaCare’s GMP operations are part of a large, diversified CRO infrastructure. OrganaBio’s GMP operations are purpose-built for the cell therapy starting material use case, with quality systems designed specifically for the donor characterization and processing requirements that cell therapy programs need.
Donor Characterization and KIR Genotyping
OrganaBio performs KIR genotyping on every donor in the leukopak program. This is a differentiator in the NK cell therapy space, where donor KIR profile is a meaningful variable in allogeneic program design. HemaCare does not market KIR genotyping as a standard donor characterization feature.
Both suppliers offer extensive donor health screening and HLA typing as part of their characterization panels. OrganaBio presents HLA typing and associated characterization as in-house capabilities across its donor programs.
Same-Donor RUO-to-GMP Continuity
One of OrganaBio’s structural differentiators is the ability to maintain the same donor across research-use and GMP phases of a program. For programs characterizing immune responses or manufacturing processes that depend on donor-specific variables, the ability to use material from the same donor in the discovery phase and in the GMP manufacturing phase eliminates a comparability variable that would otherwise require additional bridging studies.
HemaCare does not market same-donor RUO-to-GMP continuity as a program feature. As part of the larger Charles River network, maintaining donor continuity across research and clinical phases would require specific program design to achieve.
Comparison Summary
| Feature | OrganaBio | HemaCare (Charles River) |
|---|---|---|
| PBMC viability (healthy donor) | Greater than 99% average (CPC-processed) | 90% minimum spec (post-thaw) |
| Receipt-to-processing time | Under 30 minutes | 18-24+ hours (overnight shipment model) |
| Processing facilities | Owned CPCs (San Diego, Chicago) | CRL-affiliated network |
| GMP capability | Yes, owned GMP infrastructure | Yes, CRL GMP platform |
| CTDMO capability | Yes, through Excellos integration | Yes, through Charles River CRO services |
| KIR genotyping | Standard on every donor | Not marketed as standard |
| Same-donor RUO-to-GMP | Yes | Not a marketed feature |
| Disease-state donors | 24+ indications (RUO) | Available across multiple indications |
| Network scale | CPCs in 2 cities, 6-city expansion | Large multi-site network |
When to Choose OrganaBio
OrganaBio is the stronger fit when cell quality per collection is the primary variable. Programs where PBMC functional capacity matters more than collection throughput, programs using the same donor across research and GMP phases, NK cell therapy programs requiring KIR-typed starting material, and programs where the decentralized CPC model reduces the overnight shipping variable in the supply chain are the contexts where OrganaBio’s structural choices produce better outcomes than the large-network centralized model.
The Excellos integration means that OrganaBio’s CTDMO capability now spans from apheresis coordination through downstream manufacturing under one quality system. For programs that want a single-source relationship rather than managing multiple supplier relationships, OrganaBio’s end-to-end capability is a practical simplification.
When HemaCare (Charles River) May Fit Better
HemaCare’s scale advantage is real. Programs that need very high collection volumes, programs enrolled at sites that are geographically distant from OrganaBio’s CPC network, and programs that benefit from the integrated CRO infrastructure of Charles River across multiple services are legitimate cases for choosing HemaCare. If your priority is throughput and you are operating in markets well-served by HemaCare’s collection network, their scale matters.
The tradeoff is the overnight processing model and the network vs. owned-facility structure. For most immunology research applications with healthy donor material, that tradeoff is acceptable. For programs where starting material quality is on the critical path, it is not.
Frequently Asked Questions
Is HemaCare now part of Charles River Laboratories?
Yes. Charles River Laboratories acquired HemaCare in 2020. HemaCare operates as the cell therapy starting material business within CRL’s broader CRO and CDMO platform. The HemaCare brand name remains in use for the leukopak and PBMC product line.
How does OrganaBio’s 30-minute standard compare to HemaCare’s processing timeline?
OrganaBio’s 30-minute standard refers to the time from receipt of leukapheresis product at the Cell Processing Center to the first centrifuge spin. For collections performed at or near a CPC, this means processing begins within 30 minutes of collection completion. HemaCare’s centralized processing model for out-of-market collections involves overnight shipment, meaning processing typically begins 18-24 hours after collection. For collections performed at HemaCare-affiliated sites, the timeline depends on facility proximity.
Can OrganaBio support the same collection volumes as HemaCare?
OrganaBio’s CPC network is designed for programs where quality per collection is the priority. For very high volume programs requiring collections across dozens of sites simultaneously, HemaCare’s larger network may have a logistical advantage. OrganaBio’s 6-city expansion roadmap is extending its network reach, but current geographic coverage is San Diego and Chicago. Programs evaluating both suppliers should map their enrollment geography against the CPC network’s current reach.
Does OrganaBio offer the same disease-state donor portfolio as HemaCare?
OrganaBio offers disease-state PBMC donors across 24+ indications for research use (RUO). These are research-use materials for discovery, drug screening, and biomarker work. They are not GMP starting material for autologous manufacturing. HemaCare also offers disease-state products across a range of indications. Both suppliers’ disease-state materials are RUO products.
What is the difference between comparing OrganaBio’s average viability and HemaCare’s minimum spec?
A minimum specification defines where a supplier’s quality control releases product. It is a floor. An average performance number describes where typical product from that supplier lands. OrganaBio’s greater than 99% average for CPC-processed healthy donor material is documented average performance for fresh material processed under the 30-minute standard. HemaCare’s 90% minimum is the floor below which they would not release product. Comparing these two numbers directly is comparing a typical result against a minimum threshold, which is a different standard. Researchers evaluating both suppliers should request certificate of analysis data across recent batches to compare actual lot-to-lot performance, not just the published specifications.
Working With OrganaBio
If you are in an active vendor evaluation and need to understand what OrganaBio’s product specifications and logistics look like for your specific program, the CTDMO team works through the details directly: viability data from recent collections, COA examples, regulatory documentation, and how the CPC network’s coverage maps to your enrollment geography.
Contact OrganaBio to discuss your program’s starting material requirements.
